康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09966 康宁杰瑞制药-B

交易中 06-15 10:24:51

7.300

+0.200

+2.82%

最高7.320	最低7.200	成交量25.70万
今开7.200	昨收7.100	日振幅1.69%
总市值70.74亿	流通市值70.74亿	总股本9.69亿
成交额186.63万	换手率0.03%	流通股本9.69亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09966","market":"HK","secType":"STK","nameCN":"康宁杰瑞制药-B","latestPrice":7.3,"timestamp":1781489367142,"preClose":7.1,"halted":0,"volume":257000,"delay":0,"changeRate":0.028169014084507067,"floatShares":969000000,"shares":969000000,"eps":-0.12,"marketStatus":"交易中","change":0.2,"latestTime":"06-15 10:24:51","open":7.2,"high":7.32,"low":7.2,"amount":1866330,"amplitude":0.016901,"askPrice":7.3,"askSize":8000,"bidPrice":7.25,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-0.133537,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1781496000000},"marketStatusCode":2,"adr":0,"listingDate":1576080000000,"exchange":"SEHK","adjPreClose":7.1,"openAndCloseTimeList":[[1781487000000,1781496000000],[1781499600000,1781510400000]],"volumeRatio":0.744471,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09966/wiki","defaultTab":"wiki","newsList":[{"id":"2642744524","title":"智通港股早知道 | 美国5月CPI同比上涨4.2% 工信部：加强高端光电芯片和器件研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2642744524","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642744524?lang=zh_cn&edition=full","pubTime":"2026-06-11 07:42","pubTimestamp":1781134977,"startTime":"0","endTime":"0","summary":"热门中概股多数下跌，纳斯达克中国金龙指数跌0.28%。美国5月CPI同比上涨4.2%美国劳工部10日发布的数据显示，受能源价格上涨推动，美国5月消费者价格指数同比上涨4.2%，创2023年5月以来新高。其他在产锂精矿工厂的运营不受此次事件影响。报道称，蚂蚁、General Atlantic和Silver Lake代表均不予置评。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452909.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0034235303.USD","IE00BVYPNP33.GBP","LU2896262040.SGD","IE00BZ1G4Q59.USD","IE0002270589.USD","LU0070217475.USD","LU1989772923.USD","IE00BK4W5L77.USD","LU2764263203.CNY","LU0965509101.SGD","LU0234570918.USD","BK1574","LU2360108059.USD","SGXZ99366536.SGD","LU0320765059.SGD","LU1974910355.USD","LU2242649171.HKD","LU1718418525.SGD","LU0210533765.USD","LU1162221912.USD","LU0133085943.USD","LU1813983027.USD","LU0823434583.USD","BK1586","LU1803068979.SGD","LU2357305700.SGD","LU1066051811.HKD","QCMD","IE00B19Z9P08.USD","BK4585","LU0053666078.USD","IE00BZ08YR35.GBP","LU2168564065.EUR","LU2286300806.USD","LU1807302812.USD","LU1069344957.HKD","LU2111349929.HKD","LU0511384066.AUD","LU0784385840.USD","LU2471134796.USD","SG9999002224.SGD","09966","IE00BFSS8Q28.SGD","LU2065169927.USD","LU0057025933.USD","LU1642822529.SGD","LU0787776722.HKD","LU2756315318.SGD","LU0048584097.USD","LU0124676726.USD","LU1951198990.SGD","QCOM","BK1191","LU2430703251.USD","LU1935042488.USD","LU0203345920.USD","LU0786609619.USD","LU1066051225.USD","LU2433249047.HKD","LU2092937221.SGD","IE00BJJMRX11.SGD","BK4561","LU1127390331.HKD","00658","BK4575","LU0820561909.HKD","LU0345769631.USD","LU1232071149.USD","LU2347655073.USD","BK4604","LU2039709279.SGD","LU2242650005.HKD","LU0708995401.HKD","IE00B1BXHZ80.USD","LU0072462426.USD","LU0006306889.USD","LU0079474960.USD","LU0274383776.USD","LU1066051498.USD","LU2236285917.USD","LU1935043023.USD","LU2361044865.SGD","BK0197","LU1046421795.USD","LU0170899867.USD","LU1242518857.USD","LU0719512351.SGD","LU0314104364.USD","LU1691799644.USD","LU2471134879.HKD","BK0183","LU0345770993.USD","LU1778281490.HKD","LU1934455194.USD","QCMU","LU0154236417.USD","LU0795875086.SGD","BK1521","LU0724617625.USD","IE00BK4W5M84.HKD","LU2250418816.HKD","LU2089284900.SGD","LU2065171311.SGD","LU2106854487.HKD","LU1226288253.USD","LU0158827781.USD","LU2271345857.HKD","LU2298321311.HKD","IE00B1XK9C88.USD","LU0203347892.USD","LU2462157665.USD","LU1037948897.HKD","LU1923623000.USD","LU0215105999.USD","LU1917777945.USD","LU2417539215.USD","LU2420271590.USD","LU2023250504.SGD","IE00BZ08YS42.EUR","BK1546","LU0143551892.USD","LU0061475181.USD","LU2125909593.SGD","LU1629891620.HKD","LU2244417387.USD","IE0009356076.USD","LU0140636845.USD","BK0196","LU0553294199.USD","LU0957808578.USD","LU0316494557.USD","LU0965509283.SGD","LU0985320562.USD","LU1066053197.SGD","LU0476273544.USD","LU2089283258.USD","LU2360106780.USD","LU0109391861.USD","LU2473716301.USD","LU2999663052.SGD","IE00B5MMRT66.SGD","BK4551","LU2237443382.USD","LU1261432733.SGD","GB00BDT5M118.USD","LU1951200564.SGD","LU0203201768.USD","AVGX","BK1526","LU1267930813.SGD","LU0689472784.USD","LU1935043536.SGD","LU0965509010.AUD","LU2764263039.SGD","LU2023250843.SGD","LU1301847155.USD","LU1815336760.USD","SG9999011175.SGD","LU1934455277.USD","LU1202635105.USD","BK1161","LU0784384876.USD","LU2505996509.AUD","SG9999001440.SGD","LU0868494708.USD","LU1084165304.USD","LU2133065610.SGD","LU0210528500.USD","LU1868836757.USD","01277","LU0640476718.USD","LU0642271901.SGD","LU0061474960.USD","LU0345769128.USD","LU2462591350.SGD","AVL","IE00B3S45H60.SGD","LU2108987350.USD","IE00BDGV0183.EUR","IE0008369823.USD","LU1008478684.HKD","LU2089985449.USD","BK4588","BK4543","LU0082616367.USD","LU0792757196.USD","LU2361045086.USD","MUU","BK0155","LU2065171402.SGD","LU1670627923.USD","IE0004445015.USD","LU2463028550.USD","LU1003077747.HKD","IE00BWXC8680.SGD","LU1712237335.SGD","LU1720051108.HKD","LU1732800096.USD","BK4612","LU2764262908.HKD","IE00BMCWC346.EUR","LU0353189763.USD","LU2168563687.JPY","LU0158827948.USD","LU0345768740.USD","LU0211328371.USD","LU0784385170.HKD","LU2211814178.USD","LU2048586759.USD","LU0795875169.SGD","LU1868837136.USD","LU2054465674.USD","LU2355687059.USD","LU1145028129.USD","LU1226288170.HKD","IE00BVYPNW00.USD","LU2237443622.USD","LU2461242641.AUD","LU2860962120.EUR","LU0859254822.USD","LU0211327993.USD","LU1670710661.SGD","LU0308772762.SGD","IE00BJTD4N35.SGD","CHSTY","IE00BKDWB100.SGD","LU1623119135.USD","IE0004445239.USD","SG9999003800.SGD","IE00B19Z3581.USD","LU0942090050.USD","LU0320765646.SGD","IE00BJTD4V19.USD","LU0256863811.USD","LU0326950275.SGD","LU0444973449.USD","LU2213496289.HKD","MU","LU1935042215.USD","SG9999000418.SGD","LU1226287529.USD","LU2272731865.HKD","LU1670756490.USD","LU0315179316.USD","IE00BGHQF631.EUR","LU0106261372.USD","LU1951186391.HKD","BK1589","LU0225283273.USD","LU0949170772.SGD","LU1960683339.HKD","LU2487616109.SGD","LU1152091754.HKD","LU1267930490.SGD","IE00B19Z9Z06.USD","LU0234572021.USD","AVGU","LU2272731600.USD","IE0034235188.USD","LU0979878070.USD","IE00BSNM7G36.USD","LU0472753341.HKD","LU0310799852.SGD","LU0417517546.SGD","LU1803068623.USD","LU2347655156.SGD","IE00B42XCP33.USD","LU0823434740.USD","BK1205","LU2023250330.USD","LU0672654240.SGD","LU0354030438.USD","LU2272731782.SGD","LU2125154935.USD","BK4554","IE00B3PB1722.GBP","LU2247934214.USD","00031","LU0912757837.SGD","LU2083900584.USD","IE00BQXX3C00.GBP","BK0182","002466","BK0233","LU0127658192.USD","IE00B894F039.SGD","LU0266013472.USD","LU0788109477.HKD","LU1153585028.USD","HK0000914686.HKD","SGXZ81514606.USD","IE0001KFT4U8.USD","IE00BLSP4239.USD","LU1868837300.USD","MUD","LU0545039389.USD","LU0256863902.USD","LU1923622614.USD","LU1400636657.SGD","LU2471134523.USD","LU2168564222.USD","QCML","BK4581","LU2322448957.HKD","LU0251132253.USD","IE00BN29S564.USD","LU0354030511.USD","LU2063271972.USD","BK0028","IE00BMPRXQ63.HKD","BK4566","BK4605","BK1179","AVGW","LU2750360641.GBP","IE00B5949003.HKD","LU0820561818.USD","IE00BJLML261.HKD","IE00B19Z3B42.SGD","LU1323610961.USD","LU0187121727.USD","LU2168564149.EUR","LU0238689110.USD","BK4553","LU0011850046.USD","LU1035775433.USD","LU1670711040.USD","LU2954938101.SGD","LU2168564495.EUR","LU2592432038.USD","SG9999004303.SGD","LU0061474705.USD","LU0080751232.USD","LU0323591593.USD","LU1989764748.USD","LU2237957811.SGD","LU0289961442.SGD","LU0880133367.SGD","LU2265009873.SGD","LU2756315664.SGD","LU1226287875.USD","LU1935042991.SGD","BK4141","LU1992135399.USD","BK1518","LU0889565833.HKD","LU0444971666.USD","00354","LU1868836591.USD","SG9999015978.USD","LU2458330243.SGD","IE00BJJMRY28.SGD","LU0198837287.USD","IE00BMPRXN33.USD","LU2237443978.SGD","LU0056508442.USD","BK0077","LU2458330169.SGD","HK0000165453.HKD","BK4579","LU1548497426.USD","LU0957791311.USD","IE00B543WZ88.USD","AVGO","IE00B7SZLL34.SGD","IE00BGHQDM52.EUR","LU0348723411.USD","SG9999004220.SGD","LU1720051017.SGD","LU0289739343.SGD","LU2361044949.HKD","LU1244550577.SGD","LU0726765562.USD","BK1515","LU1988902786.USD","LU2095319765.USD","IE00B7KXQ091.USD","LU2357627491.SGD","LU2471134952.CNY","LU1993786604.SGD","LU1242518931.SGD","LU2746668974.SGD","LU1244550221.USD","SGXZ23171101.USD","LU2720916845.USD","LU0203202063.USD","01093","LU0097036916.USD","LU2087625088.SGD","LU1280957306.USD","LU0868494617.USD","LU0964807845.USD","IE00BN8TJ469.HKD","LU0345770308.USD","LU0353189680.USD","IE00BMPRXR70.SGD","LU2543165471.USD","LU2505996681.GBP","IE0005OL40V9.USD","IE00BZ08YT58.USD","LU1852331112.SGD","LU0784383803.USD","BK4573","LU1670628061.USD","LU2041044095.USD","LU1496350502.SGD","LU0820562030.AUD","LU0661504455.SGD","IE00B775H168.HKD","IE00BYV24P56.USD","LU1400636574.HKD","LU0314109678.HKD","IE00BQXX3D17.EUR","LU2028103732.USD","LU2211815571.USD","LU1267930730.SGD","IE00BKVL7J92.USD","IE00BZ9MQY76.HKD","SG9999015945.SGD","LU1064131342.USD","LU1366192091.USD","LU2279689827.SGD","LU0345768153.USD","HK0000532082.HKD","LU0683600562.USD","LU2931357623.SGD","BK4534","01763","LU0174119429.USD","LU2023251221.USD","LU2746668461.USD","LU1670711123.USD","LU0276348264.USD","LU1814569148.SGD","BK1155","LU2210149790.SGD","LU1152091168.USD","AVS","IE00B4JS1V06.HKD","IE00BKPKM429.USD","LU2430703178.SGD","LU2462591277.SGD","LU2360032135.SGD","LU0738911758.USD","LU1815333072.USD","LU1934455863.HKD","LU0943347566.SGD","BK4532","IE00B775SV38.USD","LU0069063385.USD","09696","HK0000914660.USD","LU1804176565.USD","BK4515","LU1674673691.USD","BK4512","BK4527","LU1989772840.SGD","LU2125909247.SGD","IE00BLSP4452.SGD","LU0689626769.HKD","LU1645745479.HKD","LU2456880835.USD","BK1222","AVGG","LU0072913022.USD","LU0210536198.USD","SG9999002232.USD","LU1551013425.SGD","LU2637965513.SGD","LU1823568750.SGD","IE00B031HY20.USD","LU2237438978.USD","LU1551013342.USD","SGXZ51526630.SGD","LU1992135472.HKD","LU2125154778.USD","LU0466842654.USD","LU1989764664.SGD","IE00BBT3K403.USD","LU1366333091.USD","IE00BVYPNV92.GBP","IE00BQXX3F31.USD","IE00BVYPNQ40.USD","BK4598","LU2210150020.SGD","LU2403377893.USD","LU2237443895.HKD","LU2430703095.HKD","SG9999015952.SGD","LU0109392836.USD","LU2237957902.USD","MULL","BK4533","LU1226287792.SGD","LU2237443465.HKD","LU0081259029.USD","LU0889566641.SGD","SG9999015986.USD","LU2750360997.AUD","LU2602419157.SGD","LU0965508806.USD","LU2322448791.USD","IE0008368742.USD","IE00BFSS7M15.SGD","LU1119994496.HKD","LU0501845795.SGD","LU1244550494.USD","LU0861579265.USD","LU0949170426.SGD","LU1670710588.SGD","LU1868836914.USD","SG9999001424.SGD","LU1674673428.USD","BK1178","LU0067412154.USD","LU0157215616.USD","LU1316542783.SGD","LU2065170008.USD","LU1400636491.USD","LU1328277881.USD","LU2237443549.SGD","LU1037948541.HKD","LU0096364046.USD","LU1914381329.SGD","LU0096362180.USD","LU1732799900.SGD","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642842817","title":"康宁杰瑞制药-B(09966)：安尼妥单抗(KN026)一线治疗HER2阳性晚期乳腺癌的III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2642842817","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642842817?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:05","pubTimestamp":1781089518,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，与石药集团有限公司附属公司上海津曼特生物科技有限公司合作开发的安尼妥单抗联合注射用多西他赛用于人类表皮生长因子受体2阳性晚期乳腺癌一线治疗的III期临床研究，经独立数据监察委员会评估，成功达到预先设定的主要终点无进展生存期，结果具有显著的统计学和临床双重意义。曲妥珠单抗联合帕妥珠单抗和多西他赛目前仍是国内外HER2+晚期乳腺癌一线治疗的首选方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09966","BK4134","BK1161","BK1574","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164726076","title":"康宁杰瑞制药-B：安博利单抗（KN026）一线治疗HER2+晚期乳腺癌III期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1164726076","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164726076?lang=zh_cn&edition=full","pubTime":"2026-06-10 19:01","pubTimestamp":1781089276,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B宣布，其核心候选药物安博利单抗（研发代号：KN026）在一线治疗HER2阳性晚期乳腺癌的III期临床研究中，成功达到了预设的主要研究终点。这项关键性研究的积极结果，标志着该药物在攻克这一重大疾病领域迈出了坚实的一步，为其后续的上市申请奠定了重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641193035","title":"康宁杰瑞制药-B：执行董事及管理层增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2641193035","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641193035?lang=zh_cn&edition=full","pubTime":"2026-06-05 08:22","pubTimestamp":1780618920,"startTime":"0","endTime":"0","summary":"　　康宁杰瑞制药-B发布公告，公司董事会已获徐霆博士告知，彼于2026年6月4日以自有资金在公开市场购入合共55.4万股公司普通股。徐霆博士及有关管理层成员购入的所有股份总代价为498.5万港元，相当于每股股份约7.375港元的平均购买价。紧随本次股份增持后，徐霆博士直接及间接持有合共3.14亿股股份，占公司已发行股份总数的约32.4%。在遵守适用法律及法规的前提下，徐霆博士及有关管理层成员并不排除其可能适时进一步增持公司股份的可能性。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-06-05/doc-iniaicuz1949381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120337363","title":"康宁杰瑞制药-B6月4日回购15.60万股股份，总额约110.85万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120337363","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120337363?lang=zh_cn&edition=full","pubTime":"2026-06-05 08:06","pubTimestamp":1780618003,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B于2026年6月5日发布公告，披露公司在2026年6月4日进行股份回购，回购数量为156,000股，占回购前已发行股份总数约0.0161%。本次回购价格区间介乎每股7.04港元至7.15港元，合计付出约110.85万港元。公告显示，公司购回授权于2025年6月12日获股东大会通过，可购回股份总数为96,218,980股；截至目前，已在交易所等渠道累计购回2,923,000股，占授权通过当日公司已发行股本约0.3038%。公司同时确认，本次回购严格遵守香港联交所之上市规则及相关法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康宁杰瑞制药-B6月4日回购15.60万股股份，总额约110.85万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641935651","title":"康宁杰瑞制药-B(09966)6月4日斥资110.85万港元回购15.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641935651","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641935651?lang=zh_cn&edition=full","pubTime":"2026-06-05 08:04","pubTimestamp":1780617860,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年6月4日斥资110.85万港元回购15.6万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149865177","title":"康宁杰瑞制药-B：股份回购总代价达499万港元，每股作价7.375港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149865177","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149865177?lang=zh_cn&edition=full","pubTime":"2026-06-05 08:02","pubTimestamp":1780617734,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B（Alphamab Oncology）宣布，其股份回购计划已累计支付总代价达499万港元，每股平均作价为7.375港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112268190","title":"康宁杰瑞制药-B2026年5月股份变动月报：新增发行88,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1112268190","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112268190?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:52","pubTimestamp":1780570348,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B于2026年6月4日披露截至2026年5月31日的证券变动月报表。月报显示，公司本月法定/注册股本无变化，仍为25,100,000,000股普通股，面值USD 0.000002，法定/注册股本总额维持USD 50,200。库存股份数量维持在5,719,000股不变，已发行股份总数由974,293,697股增至974,381,697股。根据首次公开发售后购股权计划，本月因行使股份期权新增发行普通股88,000股，行使期权所得资金总额为HKD 421,476；另有48,000股购股权在本月失效。首次公开发售前的两项购股权计划均无变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640993958","title":"康宁杰瑞制药-B(09966)：JSKN016的最新研究成果于2026年ASCO年会呈列","url":"https://stock-news.laohu8.com/highlight/detail?id=2640993958","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640993958?lang=zh_cn&edition=full","pubTime":"2026-06-02 08:27","pubTimestamp":1780360021,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，JSKN016治疗HER2-局部晚期或转移性BC的I期临床研究的最新研究成果，已于2026年5月29日至6月2日举行的2026年 ASCO年会上，于壁报展示期间公布。　　该研究结果为JSKN016在一线治疗、围手术期联合化疗、免疫治疗及其他靶向治疗的探索奠定了坚实基础。目前，JSKN016已开展单药和联合疗法治疗肺癌、BC 等多项II期临床研究，治疗TNBC的III期临床研究正在进行中，有望为患者带来更高效、安全的治疗选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260602/32266957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640981528","title":"康宁杰瑞制药-B(09966)：安尼妥单抗(KN026)新辅助治疗BC的III期临床研究结果于2026 ASCO年会以LBA口头报告形式呈列","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981528","media":"智通财经","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640981528?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:18","pubTimestamp":1780273113,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，与石药集团附属公司津曼特生物合作开发的安尼妥单抗联合注射用多西他赛新辅助治疗HER2+ BC的III期临床研究的显著性结果已于2026 ASCO年会以LBA口头报告形式呈列。KN026-004是一项随机、对照、开放、多中心III期临床研究，旨在评估安尼妥单抗联合HB1801±卡铂对比曲妥珠单抗联合帕妥珠单抗及多西他赛±卡铂在早期及局部晚期HER2+ BC新辅助治疗中的疗效与安全性，主要终点为由BIRC评估的 tpCR。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1161","09966","BK4190","III","BC","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640989809","title":"智通港股早知道 | 2026年国家医保目录调整工作方案发布 汇量科技(01860)Q1收入同比增长32.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640989809","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640989809?lang=zh_cn&edition=full","pubTime":"2026-06-01 07:01","pubTimestamp":1780268492,"startTime":"0","endTime":"0","summary":"自2027年起，截止日期将固定为方案发布之日。成分股调整将于2026年6月12日(星期五)收市后实施，并于2026年6月15日(星期一)起生效。拟发行人民币股份事宜将取决于市场状况及必要的监管批准。目前，双方的合作进展顺利。要约价较股份于2024年8月30日在联交所所报收市价每股0.28港元折让约10.71%。根据捷利交易宝数据，截至5月29日16时，公开招股部分共录得券商孖展资金高达775.92亿港元，以公开发售集资额0.684亿港元计算，孖展超额认购高达1133.38倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1328277881.USD","LU0067412154.USD","01199","LU1152091168.USD","BK1173","IE0008368742.USD","LU0072913022.USD","SG9999004220.SGD","BK1137","BK1515","LU0140636845.USD","02553","LU1226287529.USD","LU1807302812.USD","LU0880133367.SGD","BK1613","BK1574","BK1161","LU0314109678.HKD","LU0326950275.SGD","BK1586","IE00BZ08YS42.EUR","LU1951186391.HKD","IE0008369823.USD","LU1960683339.HKD","IE00BZ08YT58.USD","LU1152091754.HKD","BK1590","IE00B5MMRT66.SGD","09966","HK0000165453.HKD","LU1008478684.HKD","VXUS","BK1521","LU1993786604.SGD","IE00B543WZ88.USD","01860","01093","LU1226287875.USD","BK1518","BK1191","BK4588","BK4585","IE00B031HY20.USD","LU0315179316.USD","LU1226287792.SGD","BK1535","IE00BZ08YR35.GBP","LU1813983027.USD","LU1226288253.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639862325","title":"康宁杰瑞制药-B(09966)：恩尼妥® (安尼妥单抗注射液)获国家药品监督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2639862325","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639862325?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:09","pubTimestamp":1780045775,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B 发布公告，与石药集团有限公司附属公司上海津曼特生物科技有限公司合作开发的恩尼妥 已获中国国家药品监督管理局批准上市，联合化疗用于治疗既往至少接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性胃癌╱胃食管结合部腺癌成人患者。不良反应主要为化疗主导的血液学毒性，临床易处理，可管可控;与同类竞品相比，心脏毒性、腹泻以及输注反应发生率低，有显著安全性优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","09966","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638599035","title":"港股异动 | 康宁杰瑞制药-B(09966)涨超8% 2026年ASCO年会召开在即 公司有研究入选LBA","url":"https://stock-news.laohu8.com/highlight/detail?id=2638599035","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638599035?lang=zh_cn&edition=full","pubTime":"2026-05-26 15:33","pubTimestamp":1779780829,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B(09966)盘中涨超8%，截至发稿，涨7.06%，报10.01港元，成交额2311.83万港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260526/20260526153444_87767.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260526/20260526153444_87767.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4585","VXUS","BK1161","BK1574","BK4588","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637362263","title":"港股异动 | 康宁杰瑞制药-B(09966)涨超5% 恩沃利单抗新适应症III期临床完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2637362263","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637362263?lang=zh_cn&edition=full","pubTime":"2026-05-22 11:31","pubTimestamp":1779420681,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康宁杰瑞制药-B涨超4%，截至发稿，涨4.32%，报9.18港元，成交额811.35万港元。消息面上，5月22日，康宁杰瑞生物制药宣布，恩维达新辅助/辅助治疗可切除非小细胞肺癌的Ⅲ期临床研究，已完成全部患者入组。这一里程碑标志着恩维达在早期肺癌围手术期治疗领域取得重要进展，有望为肺癌患者带来更便捷、更安全的皮下免疫治疗新方案。目前恩维达还有多个临床研究在进行中，进一步拓展适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444926.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","BK4585","BK1574","BK4134","BK4588","09966","BK1161","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136309772","title":"康宁杰瑞制药-B：5月21日发行88,000股，发行价约4.79港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136309772","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136309772?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:36","pubTimestamp":1779356168,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B（股票代码：09966）于2026年5月21日发布公告，基于其于2020年5月25日采纳并于2024年6月12日修订的首次公开发行后购股权计划，行使期权并发行新股合计88,000股。本次新增股份占变动前已发行股本的约0.0091%。\n公告显示，此次发行的每股价格为4.79港元（四舍五入），共筹得约42.15万港元。变动后公司已发行股本为968,662,697股，库藏股数量维持5,719,000股，总股本增至974,381,697股。公司确认本次发行已依据董事会正式授权并遵照相关上市规则及法律法规。公告由执行董事徐霆签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"康宁杰瑞制药-B：5月21日发行88,000股，发行价约4.79港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637389179","title":"康宁杰瑞制药-B(09966)因期权获行使而发行8.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2637389179","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637389179?lang=zh_cn&edition=full","pubTime":"2026-05-21 17:32","pubTimestamp":1779355924,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年5月21日，该公司因于2020年5月25日采纳及2024年6月12日修订的首次公开发售后购股权计划下行使期权而发行8.8万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127168798","title":"康宁杰瑞制药-B授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1127168798","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127168798?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:37","pubTimestamp":1779266227,"startTime":"0","endTime":"0","summary":"康宁杰瑞生物制药有限公司根据最新公告，计划向董事授予股份购回授权，购回规模最高可达公司已发行股本总数的10%。截至本次授权日，公司已发行股本为968,574,697股，对应回购数量为96,857,469股。公司已宣布将于2026年6月12日（星期五）上午十时正召开年度股东大会，对包括该购回授权在内的多项议案进行审议。董事会强调，是否及何时启动股份购回将取决于市场情况及公司资金安排。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康宁杰瑞制药-B授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636046305","title":"港股异动 | 创新药概念股全线下挫 全球债市抛售潮初现 高利率或冲击行业估值及融资端","url":"https://stock-news.laohu8.com/highlight/detail?id=2636046305","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636046305?lang=zh_cn&edition=full","pubTime":"2026-05-18 11:38","pubTimestamp":1779075485,"startTime":"0","endTime":"0","summary":"消息面上，霍尔木兹海峡持续封锁，正推动油价攀升至每桶105美元以上。全球债券市场抛售潮征兆已现。美国10年期国债收益率升至4.5%以上，日本30年期国债收益率首次突破4%，英国长期国债收益率则升至28年来的最高水平，引发市场对于未来全球金融环境趋紧的担忧。其中，4 月全球、美国、国内创新药投融资均呈现强劲复苏的态势。但也有分析人士指出，若全球利率环境进入更高水平且持续，将冲击创新药行业估值及融资端。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02137","09939","VXUS","03141","06978","BK4588","02171","09141","BK1515","BK1585","BK1574","BK1587","159992","09966","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635221155","title":"康宁杰瑞制药-B(09966)：JSKN033一线治疗晚期宫颈癌的II期临床研究完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221155","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635221155?lang=zh_cn&edition=full","pubTime":"2026-05-13 08:09","pubTimestamp":1778630957,"startTime":"0","endTime":"0","summary":"在早期临床研究中，JSKN033单药在经治晚期宫颈癌患者中已展现出优异疗效和可控安全性，为其一线联合治疗奠定了坚实基础。JSKN033-202是一项开放、多中心、II期临床研究，旨在评估JSKN033联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌患者的安全性、有效性及药代动力学╱药效学特征。所有患者将接受JSKN033联合顺铂或卡铂联合或不联合贝伐珠单抗的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1161","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117085218","title":"康宁杰瑞制药-B更新2026年4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1117085218","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117085218?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:01","pubTimestamp":1778144471,"startTime":"0","endTime":"0","summary":"2026年5月7日，康宁杰瑞制药-B发布截至2026年4月30日止的股份变动月报表。公司本月末的法定/注册股本数量保持在25,100,000,000股普通股，面值为每股USD 0.000002，总额USD 50,200，与上月一致。根据公告，首次公开发售前及后购股权计划未发生新股发行或股份转让。其中，首次公开发售后购股权计划有18,000份已失效，余下股份期权结存1,112,000份。公司表示，所有股份期权及限制性股份计划的变动均已获得必要批准，并遵守香港联交所《上市规则》及相关法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alphamab.com","stockEarnings":[{"period":"1week","weight":0.0216},{"period":"1month","weight":-0.2487},{"period":"3month","weight":-0.1744},{"period":"6month","weight":-0.3377},{"period":"1year","weight":-0.1456},{"period":"ytd","weight":-0.2755}],"compareEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0294},{"period":"6month","weight":-0.0485},{"period":"1year","weight":0.0284},{"period":"ytd","weight":-0.0356}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康宁杰瑞生物制药是一家主要从事肿瘤生物制剂研发、制造及商业化的投资控股公司。该公司高度差异化的内部管线由处于不同研发阶段的ADCs、单克隆抗体及双特异性抗体肿瘤药物组成。该公司的候选药物包括KN046（PD-L1/CTLA-4双特异性抗体）, KN026（抗HER2双特异性抗体）, KN035（皮下注射PD-L1）, JSKN003（HER2双表位ADC）等，用于1L sq NSCLC、乳腺癌 2+HER L1、晚期实体瘤、HER2表达实体瘤等适应症。","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.117313},{"month":2,"riseRate":0.571429,"avgChangeRate":0.192959},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.039472},{"month":4,"riseRate":0.857143,"avgChangeRate":0.098183},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.031094},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.057006},{"month":7,"riseRate":0.333333,"avgChangeRate":0.059359},{"month":8,"riseRate":0.333333,"avgChangeRate":0.022561},{"month":9,"riseRate":0.333333,"avgChangeRate":0.158319},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.030396},{"month":11,"riseRate":0.5,"avgChangeRate":0.042537},{"month":12,"riseRate":0.5,"avgChangeRate":-0.017716}],"exchange":"SEHK","name":"康宁杰瑞制药-B","nameEN":"ALPHAMAB-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康宁杰瑞制药-B,09966,康宁杰瑞制药-B股票,康宁杰瑞制药-B股票老虎,康宁杰瑞制药-B股票老虎国际,康宁杰瑞制药-B行情,康宁杰瑞制药-B股票行情,康宁杰瑞制药-B股价,康宁杰瑞制药-B股市,康宁杰瑞制药-B股票价格,康宁杰瑞制药-B股票交易,康宁杰瑞制药-B股票购买,康宁杰瑞制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康宁杰瑞制药-B(09966)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康宁杰瑞制药-B(09966)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}